Isn’t this already Kesimpta? https://www.businesswire.com/news/home/20240416088195/en/Genentech’s-Subcutaneous-Ocrevus-One-Year-Data-Demonstrates-Near-Complete-Suppression-of-Clinical-Relapses-and-Brain-Lesions-in-Patients-With-Progressive-and-Relapsing-Forms-of-MS?utm_source=newsletter&utm_medium=email&utm_campaign=innovationrx&cdlcid=6514937a554da33a6b7fa780§ion=deals